Table of Contents

1 Study Coverage

• 1.1 Fenofibrate Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Fenofibrate Market Size Growth Rate by Product
  • 1.4.2 Tablet
  • 1.4.3 Capsule
• 1.5 Market by End User
  • 1.5.1 Global Fenofibrate Market Size Growth Rate by End User
  • 1.5.2 Hospital
  • 1.5.3 Drug store
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Fenofibrate Market Size
  • 2.1.1 Global Fenofibrate Revenue 2014-2025
  • 2.1.2 Global Fenofibrate Sales 2014-2025
• 2.2 Fenofibrate Growth Rate by Regions
  • 2.2.1 Global Fenofibrate Sales by Regions
  • 2.2.2 Global Fenofibrate Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Fenofibrate Sales by Manufacturers
  • 3.1.1 Fenofibrate Sales by Manufacturers
  • 3.1.2 Fenofibrate Sales Market Share by Manufacturers
  • 3.1.3 Global Fenofibrate Market Concentration Ratio (CR5 and HHI)
• 3.2 Fenofibrate Revenue by Manufacturers
  • 3.2.1 Fenofibrate Revenue by Manufacturers (2014-2019)
  • 3.2.2 Fenofibrate Revenue Share by Manufacturers (2014-2019)
• 3.3 Fenofibrate Price by Manufacturers
• 3.4 Fenofibrate Manufacturing Base Distribution, Product Types
  • 3.4.1 Fenofibrate Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Fenofibrate Product Type
  • 3.4.3 Date of International Manufacturers Enter into Fenofibrate Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Fenofibrate Sales by Product
• 4.2 Global Fenofibrate Revenue by Product
• 4.3 Fenofibrate Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Fenofibrate Breakdown Data by End User

6 North America

• 6.1 North America Fenofibrate by Countries
  • 6.1.1 North America Fenofibrate Sales by Countries
  • 6.1.2 North America Fenofibrate Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Fenofibrate by Product
• 6.3 North America Fenofibrate by End User

7 Europe

• 7.1 Europe Fenofibrate by Countries
  • 7.1.1 Europe Fenofibrate Sales by Countries
  • 7.1.2 Europe Fenofibrate Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Fenofibrate by Product
• 7.3 Europe Fenofibrate by End User

8 Asia Pacific

• 8.1 Asia Pacific Fenofibrate by Countries
  • 8.1.1 Asia Pacific Fenofibrate Sales by Countries
  • 8.1.2 Asia Pacific Fenofibrate Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Fenofibrate by Product
• 8.3 Asia Pacific Fenofibrate by End User

9 Central & South America

• 9.1 Central & South America Fenofibrate by Countries
  • 9.1.1 Central & South America Fenofibrate Sales by Countries
  • 9.1.2 Central & South America Fenofibrate Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Fenofibrate by Product
• 9.3 Central & South America Fenofibrate by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Fenofibrate by Countries
  • 10.1.1 Middle East and Africa Fenofibrate Sales by Countries
  • 10.1.2 Middle East and Africa Fenofibrate Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Fenofibrate by Product
• 10.3 Middle East and Africa Fenofibrate by End User

11 Company Profiles

• 11.1 AbbVie
  • 11.1.1 AbbVie Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 AbbVie Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 AbbVie Fenofibrate Products Offered
  • 11.1.5 AbbVie Recent Development
• 11.2 Lupin
  • 11.2.1 Lupin Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Lupin Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Lupin Fenofibrate Products Offered
  • 11.2.5 Lupin Recent Development
• 11.3 Salix Pharmaceuticals
  • 11.3.1 Salix Pharmaceuticals Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Salix Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Salix Pharmaceuticals Fenofibrate Products Offered
  • 11.3.5 Salix Pharmaceuticals Recent Development
• 11.4 Vectura
  • 11.4.1 Vectura Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Vectura Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Vectura Fenofibrate Products Offered
  • 11.4.5 Vectura Recent Development
• 11.5 Cipher Pharmaceuticals
  • 11.5.1 Cipher Pharmaceuticals Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Cipher Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Cipher Pharmaceuticals Fenofibrate Products Offered
  • 11.5.5 Cipher Pharmaceuticals Recent Development
• 11.6 Rhodes Pharmaceuticals
  • 11.6.1 Rhodes Pharmaceuticals Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Rhodes Pharmaceuticals Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Rhodes Pharmaceuticals Fenofibrate Products Offered
  • 11.6.5 Rhodes Pharmaceuticals Recent Development
• 11.7 Impax Laboratories
  • 11.7.1 Impax Laboratories Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Impax Laboratories Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Impax Laboratories Fenofibrate Products Offered
  • 11.7.5 Impax Laboratories Recent Development
• 11.8 Mylan
  • 11.8.1 Mylan Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Mylan Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Mylan Fenofibrate Products Offered
  • 11.8.5 Mylan Recent Development
• 11.9 Teva
  • 11.9.1 Teva Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Teva Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Teva Fenofibrate Products Offered
  • 11.9.5 Teva Recent Development
• 11.10 Sun Pharmaceutical
  • 11.10.1 Sun Pharmaceutical Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Sun Pharmaceutical Fenofibrate Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Sun Pharmaceutical Fenofibrate Products Offered
  • 11.10.5 Sun Pharmaceutical Recent Development
• 11.11 Bausch Health
• 11.12 HETERO
• 11.13 Aurobindo Pharma
• 11.14 Cipla
• 11.15 Amneal Pharmaceuticals
• 11.16 Prinston Pharmaceutical
• 11.17 Dr. Reddys Laboratories
• 11.18 APOTEX
• 11.19 Glenmark

12 Future Forecast

• 12.1 Fenofibrate Market Forecast by Regions
  • 12.1.1 Global Fenofibrate Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Fenofibrate Revenue Forecast by Regions 2019-2025
• 12.2 Fenofibrate Market Forecast by Product
  • 12.2.1 Global Fenofibrate Sales Forecast by Product 2019-2025
  • 12.2.2 Global Fenofibrate Revenue Forecast by Product 2019-2025
• 12.3 Fenofibrate Market Forecast by End User
• 12.4 North America Fenofibrate Forecast
• 12.5 Europe Fenofibrate Forecast
• 12.6 Asia Pacific Fenofibrate Forecast
• 12.7 Central & South America Fenofibrate Forecast
• 12.8 Middle East and Africa Fenofibrate Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Fenofibrate Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
The global Fenofibrate market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Fenofibrate market based on company, product type, end user and key regions.

This report studies the global market size of Fenofibrate in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Fenofibrate in these regions.
This research report categorizes the global Fenofibrate market by top players/brands, region, type and end user. This report also studies the global Fenofibrate market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AbbVie
Lupin
Salix Pharmaceuticals
Vectura
Cipher Pharmaceuticals
Rhodes Pharmaceuticals
Impax Laboratories
Mylan
Teva
Sun Pharmaceutical
Bausch Health
HETERO
Aurobindo Pharma
Cipla
Amneal Pharmaceuticals
Prinston Pharmaceutical
Dr. Reddys Laboratories
APOTEX
Glenmark

Market size by Product
Tablet
Capsule
Market size by End User
Hospital
Drug store

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Fenofibrate market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Fenofibrate market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Fenofibrate companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Fenofibrate submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Fenofibrate are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Fenofibrate market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.